Clive R Wood
Overview
Explore the profile of Clive R Wood including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
1461
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gollner A, Koster M, Nicklin P, Trieselmann T, Klein E, Vlach J, et al.
Nat Rev Drug Discov
. 2022 Apr;
21(7):475-476.
PMID: 35459938
No abstract available.
2.
Nixon A, Chen J, Sexton D, Muruganandam A, Bitonti A, Dumont J, et al.
Front Immunol
. 2015 May;
6:176.
PMID: 25954273
The therapeutic management of antibody-mediated autoimmune disease typically involves immunosuppressant and immunomodulatory strategies. However, perturbing the fundamental role of the neonatal Fc receptor (FcRn) in salvaging IgG from lysosomal degradation...
3.
Kerschbaumer R, Rieger M, Volkel D, Le Roy D, Roger T, Garbaraviciene J, et al.
J Biol Chem
. 2012 Jan;
287(10):7446-55.
PMID: 22238348
The macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine that recently emerged as an attractive therapeutic target for a variety of diseases. A diverse panel of fully human anti-MIF...
4.
Sexton D, Chen T, Martik D, Kuzmic P, Kuang G, Chen J, et al.
Biochem J
. 2009 Jun;
422(2):383-92.
PMID: 19527222
KLK1 (tissue kallikrein 1) is a member of the tissue kallikrein family of serine proteases and is the primary kinin-generating enzyme in human airways. DX-2300 is a fully human antibody...
5.
Devy L, Huang L, Naa L, Yanamandra N, Pieters H, Frans N, et al.
Cancer Res
. 2009 Feb;
69(4):1517-26.
PMID: 19208838
Inhibition of specific matrix metalloproteinases (MMP) is an attractive noncytotoxic approach to cancer therapy. MMP-14, a membrane-bound zinc endopeptidase, has been proposed to play a central role in tumor growth,...
6.
Sato A, Viswanathan M, Kent R, Wood C
Curr Opin Biotechnol
. 2006 Oct;
17(6):638-42.
PMID: 17049837
As potential therapeutics, peptides offer several advantages over small molecules (increased specificity) and antibodies (small size). Nevertheless, a number of key issues have hampered their use as drug candidates. A...
7.
Huang L, Shimaoka M, Rondon I, Roy I, Chang Q, Po M, et al.
J Leukoc Biol
. 2006 Aug;
80(4):905-14.
PMID: 16888085
LFA-1 (alpha(L)beta(2)) mediates cell-cell and cell-extracellular matrix adhesions essential for immune and inflammatory responses. One critical mechanism regulating LFA-1 activity is the conformational change of the ligand-binding alpha(L) I domain...
8.
Nixon A, Wood C
Curr Opin Drug Discov Devel
. 2006 Mar;
9(2):261-8.
PMID: 16566296
The control of proteolysis in an organism is achieved under normal circumstances through a balance of protease production, degradation and inactivation, via interaction with an endogenous inhibitor. When one of...
9.
Sheppard K, Fitz L, Lee J, Benander C, George J, Wooters J, et al.
FEBS Lett
. 2004 Sep;
574(1-3):37-41.
PMID: 15358536
Engagement of the immunoinhibitory receptor, programmed death-1 (PD-1) attenuates T-cell receptor (TCR)-mediated activation of IL-2 production and T-cell proliferation. Here, we demonstrate that PD-1 modulation of T-cell function involves inhibition...
10.
Brown J, Dorfman D, Ma F, Sullivan E, Munoz O, Wood C, et al.
J Immunol
. 2003 Jan;
170(3):1257-66.
PMID: 12538684
Programmed death-1 ligand (PD-L)1 and PD-L2 are ligands for programmed death-1 (PD-1), a member of the CD28/CTLA4 family expressed on activated lymphoid cells. PD-1 contains an immunoreceptor tyrosine-based inhibitory motif...